Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 7/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762231 | 0.78 | AHR (0.59) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL4071447 | 0.78 | NPC1 (0.55) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL31097976 | 0.74 | MAPT (0.58) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL29408147 | 0.73 | GAA (0.54) | MAPTAHRPDK2NPC1GAA | |
| SCHEMBL29144954 | 0.73 | GAA (0.54) | MAPTAHRPDK2NPC1GAA | |
| SCHEMBL123812 | 0.73 | GAA (0.54) | MAPTAHRPDK2NPC1GAA | |
| SCHEMBL10558162 | 0.73 | BRD4 (0.40) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL37900 | 0.73 | AHR (0.50) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL29483964 | 0.73 | AHR (0.50) | MAPTAHRPDK2NPC1MAPK13 | |
| SCHEMBL17758261 | 0.71 | GAA (0.52) | MAPTAHRPDK2NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989617-B2 | Crown ether derivatives | Life Technologies Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989617-B2 | Crown ether derivatives | Life Technologies Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100047821-A1 | CROWN ETHER DERIVATIVES | Life Technologies Corporation (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100047821-A1 | CROWN ETHER DERIVATIVES | Life Technologies Corporation (US) | 2010-02-25 | — | — | US | disclosed |
| US-7579463-B2 | Crown ether derivatives | Life Technologies Corporation (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579463-B2 | Crown ether derivatives | Life Technologies Corporation (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070043212-A1 | CROWN ETHER DERIVATIVES | MOLECULAR PROBES, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043212-A1 | CROWN ETHER DERIVATIVES | MOLECULAR PROBES, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047821-A1 | CROWN ETHER DERIVATIVES | NCOR1, NCOR2, NCOA2 | MAPT 3634/4885AHR 335/4885PDK2 4760/4885 |
| US-20070043212-A1 | CROWN ETHER DERIVATIVES | NCOR2, NCOR1, NCOA3 | MAPT 3494/4885AHR 1099/4885PDK2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.